Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30631460 | 1.00 | MEN1 (0.67) | MEN1KMT2APKMMAPTALDH1A1 | |
| SCHEMBL1367417 | 0.86 | MEN1 (0.65) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL15445432 | 0.85 | KMT2A (0.64) | MEN1KMT2APKMMAPTALDH1A1 | |
| SCHEMBL11001459 | 0.84 | KMT2A (0.55) | MEN1KMT2APKMMAPTALDH1A1 | |
| SCHEMBL29366579 | 0.84 | KMT2A (0.63) | MEN1KMT2APKMMAPTALDH1A1 | |
| SCHEMBL393627 | 0.84 | KMT2A (0.63) | MEN1KMT2APKMMAPTALDH1A1 | |
| SCHEMBL25082416 | 0.84 | MAPT (0.50) | MEN1KMT2APKMMAPTALDH1A1 | |
| SCHEMBL1467189 | 0.83 | MAPK1 (0.63) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL1178069 | 0.83 | KMT2A (0.58) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL12426321 | 0.83 | KMT2A (0.57) | MEN1KMT2AMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | UBE CORPORATION (JP) | 2026-02-24 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| EP-3978073-B1 | 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES | UBE CORP (JP) | 2025-10-15 | — | — | EP | disclosed |
| CN-108623561-B | Method for preparing panenonic acid compound | 中国海洋大学 | 2025-04-01 | — | — | CN | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-114174289-B | Benzotriazole derivatives | ＵＢＥ株式会社 | 2025-03-07 | — | — | CN | disclosed |
| US-20240294490-A1 | ORGANIC COMPOUND AND ELECTROCHROMIC ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-23 | — | — | US | disclosed |
| EP-0478964-A1 | Pyrazoloquinoline derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1992-04-08 | — | — | EP | disclosed |
| US-4971958-A | CALCIUM METABOLISM | BOEHRINGER MANNHEIM GMBH (DE) | 1990-11-20 | — | — | US | disclosed |
| EP-0182165-B1 | THIENYL CONDENSED-PYRAZOLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1989-08-16 | — | — | EP | disclosed |
| US-4788188-A | ANTICONVULSANTS, SEDATIVES, ANXIOLYTIC AGENTS | SANOFI (S.A.) (FR) | 1988-11-29 | — | — | US | disclosed |
| US-4690930-A | TRANQUILIZERS, ANTICONVULSANTS | SHIONOGI & CO., LTD (JP) | 1987-09-01 | — | — | US | disclosed |
| EP-0182165-A1 | Thienyl condensed-pyrazole derivatives | SHIONOGI & CO., LTD. (JP) | 1986-05-28 | — | — | EP | disclosed |
| US-4588731-A | Derivatives of isoxazolo[4,5-c]quinoline(2H)-3-one and method of preparation and use as anxiolytic agents | ROUSSEL UCLAF (FR) | 1986-05-13 | — | — | US | disclosed |
| US-4524146-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1985-06-18 | — | — | US | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4312870-A | TRANQUILIZERS, ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | KEAP1, NFE2L2, NCOR1 | MEN1 3532/4885KMT2A 347/4885PKM 1136/4885 |
| US-20230373925-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | MEN1 3962/4885KMT2A 3649/4885PKM 2482/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | MEN1 3962/4885KMT2A 3649/4885PKM 2482/4885 |
| US-20240294490-A1 | ORGANIC COMPOUND AND ELECTROCHROMIC ELEMENT | CCNL2, RER1, DNMT3L | MEN1 2247/4885KMT2A 1724/4885PKM 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.